Based on this data, we hypothesize that activation of these tumor promoting genes and increased expression of MMP2 and TGF-β1 proteins in hADSCs-IL2 could have adverse effects on tumor growth when used for the treatment of cancer patients and requires additional investigation. The gene discussed is IL2; the disease is cancer.